2024-2025 Global AI Trends Guide
Brian Carey
Partner Global Regulatory
Brian regularly advises innovative medical technology developers, medical trade associations, leading clinical laboratories, and molecular diagnostic companies through the evolving regulatory requirements to commercialize new technologies successfully. His practice focuses on addressing regulatory challenges for Laboratory Developed Tests, assessing payment under the Protecting Access to Medicare Act of 2014 (PAMA), and establishing coverage pathways with public and private payers.
Enabled a pharmaceutical to obtain the first Medicare New Technology Add on Payment (NTAP) for an oral therapy.*
Helped CMS design and create one of the first data registries in its CED program, by advising a coalition of leading academic medical centers and medical device manufacturers.*
Advised leading molecular diagnostic company on the development of the current Medicare coverage, payment, and coding challenges on the Clinical Laboratory Fee Schedule (CLFS).*
Developed novel legal arguments and assembled compelling scientific evidence that successfully reversed an adverse policy decision affecting the coding and payment for biotechnology product.*
Presented legal arguments for a new medical technology that led to the creation of a new DRG for an inpatient hospital payment.*
Represented a biotechnology client before CMS and Congress, leading to the creation of a new payment methodology for therapeutic radiopharmaceuticals based on the Average Sales Price methodology.*
Advised numerous clinical laboratories on the local coverage process with Medicare Administrative Contractors.*
*Matter handled prior to joining Hogan Lovells.